# Family-owned Italian pharmaceutical group Chiesi is expanding its U.S. footprint through a multi-billion dollar acquisition.

*biotech, business · news · 2026-04-29 · MarketScreener*

## Key points

- Chiesi is acquiring KalVista for $1.9 billion, marking its largest deal ever.
- Chiesi will finance the acquisition using both cash reserves and new debt.
- KalVista's hereditary angioedema treatment is central to Chiesi's anticipated growth in the U.S.
- Chiesi projects its revenue to grow from €3.6 billion in 2024 to €6 billion by 2030.

Family-owned Italian pharmaceutical group Chiesi is expanding its U.S. footprint through a multi-billion dollar acquisition. The company offered KalVista shareholders 27 dollars per share on Wednesday, representing a total cash consideration of 1.9 billion dollars. Following the announcement, KalVista shares surged as much as 39.1 percent on Wall Street, hitting a five-year high of 26.76 dollars. With the largest acquisition in its corporate history, Chiesi aims to bolster its rare disease portfolio and increase its market share in the United States. According to the companies, the boards of both firms have unanimously approved the transaction. An insider stated that Chiesi is financing the deal through a combination of existing cash reserves and new debt. The group currently holds 729 million euros in cash. The Italian pharmaceutical firm generated 3.6 billion euros in revenue in 2024. This figure is projected to rise to six billion euros by 2030. Chiesi expects a significant growth boost primarily from KalVista's treatment for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and painful swelling. (Reporting by Giancarlo Navach; writing by Hakan Ersen, edited by Ralf Banser. For inquiries, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and economics) or frankfurt.newsroom@thomsonreuters.com (for corporate and markets).)

**Companies:** Chiesi, KalVista
**Countries:** Italy, United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/italian-pharma-group-chiesi-to-acquire-u-s-rival-kalvista-ce7f58dada8af021)

---

Canonical: https://newsio.io/n/edadfcfb-8547-4c7b-ace7-5746dc89c732/family-owned-italian-pharmaceutical-group-chiesi-is-expanding-its-u-s-footprint
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works